RxDoctor Payments Data

Lisa Kassenoff, DO

Family Medicine · Forked River, NJNPI 1912960436

Payments from drug & device makers

$264in general payments, 2019–2025

Across 18 payments — averaging $14.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$111
  • AstraZeneca$39
  • Merck$29
  • Pfizer$16
  • GSK$15
  • Amarin Pharma, Inc.$15
  • plus $39 from 3 others

What the payments were for

  • Food & beverage$25296%
  • Education$124%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk7$111
AstraZeneca3$39
Merck2$29
Pfizer1$16
GSK1$15
Amarin Pharma, Inc.1$15
Amgen1$14
Medtronic1$13
Lilly USA, LLC1$12

How this compares

$264 in reported general payments places this provider in the 40th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$168,829
Medicare patients
358
Services billed
2,337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$120,394
JardianceEmpagliflozin42$58,306
MounjaroTirzepatide37$47,470
JanuviaSitagliptin Phosphate24$35,759
FarxigaDapagliflozin Propanediol23$35,290
RybelsusSemaglutide18$31,452
ProliaDenosumab13$22,500
EliquisApixaban12$19,376
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$17,345
MyrbetriqMirabegron18$13,881
Rosuvastatin Calcium550$8,696
SynthroidLevothyroxine Sodium77$6,597
Atorvastatin Calcium464$5,478
Gabapentin89$3,933
Valsartan74$3,430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$111$151,84693 claims
Lilly USA, LLCMounjaro$12$47,47037 claims
MerckJanuvia$29$35,75924 claims
AstraZenecaFarxiga$39$35,29023 claims
AmgenProlia$14$22,50013 claims
PfizerEliquis, Paxlovid$16$20,80624 claims
GSKTrelegy Ellipta$15$17,34515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Forked River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →